Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00658983

Enrollment

Registered

2008-04-16

Start date

2008-04-01

Completion date

2010-08-20

Last updated

2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lower Leg Ulcer

Brief summary

Compare Autologous Platelet Enriched Gel versus Metalloproteinase Inhibitor in the healing of chronic lower leg ulcers.

Interventions

OTHERAutologous Platelet Enriched Gel

Treatment with Autologous Platelet Enriched Gel

OTHERMetalloproteinase Inhibitor

Treatment with Metalloproteinase Inhibitor (Promogran)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 year or older * A non-healing chronic lower leg ulcer * Platelet ranges of 150000 per ml circulating blood

Exclusion criteria

* Presence of a tumor or metastatic disease * Hypersensitive to collagen regenerated cellulose * Hemodynamic unstable patient * Hypercoagulability * Heart decompensation or angina pectoris

Design outcomes

Primary

Measure	Time frame
Wound healing	6 weeks

Secondary

Measure	Time frame
Wound healing	6 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026